Unknown

Dataset Information

0

Antibody-drug conjugates in solid tumors: a look into novel targets.


ABSTRACT: Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly described as the "Trojan Horses" of therapeutic armamentarium, because of their capability of directly conveying cytotoxic drug (payloads) into the tumor space, thus transforming chemotherapy into a targeted agent. Three novel ADCs have been recently approved, i.e., trastuzumab deruxtecan, sacituzumab govitecan and enfortumab vedotin, respectively, targeting HER2, Trop2 and Nectin4. Thanks to progressive advances in engineering technologies these drugs rely on, the spectrum of diseases sensitive to these drugs as well as their indications are in continuous expansion. Several novel ADCs are under evaluation, exploring new potential targets along with innovative payloads. This review aims at providing a summary of the technology behind these compounds and at presenting the latest ADCs approved in solid tumors, as well as at describing novel targets for ADCs under investigation and new strategies to optimize their efficacy in solid tumors.

SUBMITTER: Criscitiello C 

PROVIDER: S-EPMC7844898 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antibody-drug conjugates in solid tumors: a look into novel targets.

Criscitiello Carmen C   Morganti Stefania S   Curigliano Giuseppe G  

Journal of hematology & oncology 20210128 1


Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly described as the "Trojan Horses" of therapeutic armamentarium, because of their capability of directly conveying cytotoxic drug (payloads) into the tumor space, thus transforming chemotherapy into a targeted agent. Three novel ADCs have been recently approved, i.e., trastuzumab deruxtecan, sacitu  ...[more]

Similar Datasets

| S-EPMC5427099 | biostudies-literature
| S-EPMC7098807 | biostudies-literature
| S-EPMC5080863 | biostudies-literature
| S-EPMC7222243 | biostudies-literature
| S-EPMC8066800 | biostudies-literature
| S-EPMC7801065 | biostudies-literature
| S-EPMC10459723 | biostudies-literature
| S-EPMC3969339 | biostudies-other
| S-EPMC6088352 | biostudies-literature
| S-EPMC8253558 | biostudies-literature